ClinicalTrials.Veeva

Menu

MSOT As Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases

C

Children's Hospital of Eastern Ontario

Status

Enrolling

Conditions

Neuromuscular Diseases

Treatments

Device: Multispectral Optoacoustic Tomography (MSOT)

Study type

Observational

Funder types

Other

Identifiers

NCT06438965
MSOT-01

Details and patient eligibility

About

The goal of this study is to learn if Multispectral Optoacoustic Tomographs (MSOT) works to diagnose and follow the course of neuromuscular diseases (NMDs) in children. MSOT scans will be obtained from muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patients with neuromuscular diseases. No additional research activities -other than MSOT - will be done during this study. Existing clinical, laboratory and imaging data from standard-of-care procedures will be correlated with the MSOT data. The expected total duration of the study is approximately 36 months. Repeated measurements will be done to evaluate disease progression and the value of MSOT in NMD.

Enrollment

240 estimated patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with neuromuscular disease

  • Children (from birth (infants that are born term) to 18 years of age) participants or consent through authorized guardian
  • Confirmed or suspected diagnosis of a neuromuscular disease (through molecular genetics, biopsy, clinical examination)

Exclusion criteria

Participants:

  • Diagnosis is not consistent with a confirmed or suspected neuromuscular disease
  • Patients with active skin lesions (e.g. infections, trauma) or confirmed genetic disorders (e.g. epidermolysis bullosa) that predisposes to skin lesion
  • Medically unstable patients
  • Tattoo on skin overlying the area to be examined
  • Missing consent form
  • Exclusion due to safety concerns of the investigator (subject who has any condition, including any physical, psychological, or psychiatric condition, which in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data and renders the subject an unsuitable candidate for the study)
  • Medication leading to increased light sensitivity

Trial design

240 participants in 1 patient group

Patient with neuromuscular disease
Description:
Muscle regions of the patients with neuromuscular diseases will be imaged using the MSOT device. Repeated measurements will be done after 6-12 months.
Treatment:
Device: Multispectral Optoacoustic Tomography (MSOT)

Trial contacts and locations

1

Loading...

Central trial contact

Hanns Lochmuller, Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems